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Abstract
Background: HIV self-testing (HIVST) has been found to be highly effective, but no cost analysis has been undertaken
to guide the design of affordable and scalable implementation strategies.
Methods: Consecutive HIV self-testers and facility-based testers were recruited from participants in a community cluster-
randomised trial (ISRCTN02004005) investigating the impact of offering HIVST in addition to facility-based HIV testing and
counselling (HTC). Primary costing studies were undertaken of the HIVST service and of health facilities providing
HTC to the trial population. Costs were adjusted to 2014 US$ and INT$. Recruited participants were asked about
direct non-medical and indirect costs associated with accessing either modality of HIV testing, and additionally
their health-related quality of life was measured using the EuroQol EQ-5D.
Results: A total of 1,241 participants underwent either HIVST (n = 775) or facility-based HTC (n = 446). The mean
societal cost per participant tested through HIVST (US$9.23; 95 % CI: US$9.14-US$9.32) was lower than through
facility-based HTC (US$11.84; 95 % CI: US$10.81-12.86). Although the mean health provider cost per participant
tested through HIVST (US$8.78) was comparable to facility-based HTC (range: US$7.53-US$10.57), the associated
mean direct non-medical and indirect cost was lower (US$2.93; 95 % CI: US$1.90-US$3.96). The mean health
provider cost per HIV positive participant identified through HIVST was higher (US$97.50) than for health facilities
(range: US$25.18-US$76.14), as was the mean cost per HIV positive individual assessed for anti-retroviral treatment
(ART) eligibility and the mean cost per HIV positive individual initiated onto ART. In comparison to the facility-
testing group, the adjusted mean EQ-5D utility score was 0.046 (95 % CI: 0.022-0.070) higher in the HIVST group.
Conclusions: HIVST reduces the economic burden on clients, but is a costlier strategy for the health provider aiming to
identify HIV positive individuals for treatment. The provider cost of HIVST could be substantially lower under less restrictive
distribution models, or if costs of oral fluid HIV test kits become comparable to finger-prick kits used in health facilities.
Keywords: HIV, HIV testing and counselling, HIV self-testing, Costs, Health-related quality of life, EQ-5D
Background
Awareness of HIV status is key to ensuring timely access
to effective HIV treatment and prevention [1, 2]. Sub-
Saharan Africa accounts for three quarters of all new
infections and HIV-related deaths [3], and despite
massive increases in funding for HIV testing services,
only one half of Africans know their HIV status [3, 4].
New targets, set by UNAIDS (“90-90-90”), and agreed to
by most African countries including Malawi, are for
90 % of Africans living with HIV to know their status by
2020, with 90 % of these retained on antiretroviral ther-
apy (ART), and 90 % of those on ART having undetect-
able viral loads [5]. Uptake, however, remains low in
hard-to-reach populations, including men and adoles-
cents, and amongst those who do have regular contact
with broader healthcare services, including pregnant
women and those with tuberculosis (TB) disease [3].
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HIV testing and counselling (HTC) continues to be
undertaken predominantly in health facilities [4], despite
strong evidence to suggest clients prefer to test in the
community [6, 7]. Community-based HTC, including
home-based and mobile services, reach HIV infected
individuals earlier in their disease progression [8], poten-
tially improving health outcomes and reducing health-
care costs of care provision [9]. Community-based HTC
may be essential to reach the 90-90-90 targets [10], but
costs tend to be higher than for facility-based HTC
services, with lower uptake of post-test HIV care services
unless facilitated linkage interventions are provided
alongside [11, 12].
HIV self-testing (HIVST) has been found to be highly
acceptable, safe and effective at achieving high coverage
rates in communities, including amongst hard-to-reach
populations of men and adolescents [13–15]. However,
no primary cost analyses have been undertaken of HIV
self-testing services in sub-Saharan Africa to inform pol-
icy, hindering efforts to design scalable implementation
strategies. We undertook a costing study to investigate
the costs to both healthcare providers and users acces-
sing either HIVST or facility-based HTC. We addition-
ally describe the health-related quality of life of users of
these services. We collected individual-level economic
data from users of both services, and undertook primary
costing studies of the two approaches, within the context
of a large cluster-randomised study investigating the
impact of offering HIVST in addition to facility-based
HTC in Blantyre, Malawi.
Methods
Study design and participants
The study recruited individuals who were participants in a
cluster-randomised trial (ISRCTN02004005) investigating
the impact of offering HIVST in addition to standard
facility-based HTC [16]. We estimated the economic costs
associated with HIVST and facility-based HTC, and add-
itionally the health-related quality of life (HRQoL) of par-
ticipants accessing either modality.
The study area included three high-density urban sub-
urbs of Blantyre, Malawi [15] with an adult population of
approximately 34,000 residents and adult HIV prevalence
of 18 % [13]. Twenty-eight clusters of approximately 1,200
adults were randomised to either HIVST or standard-of-
care (control). In all clusters, participants could access
HTC at the health facilities by self-presenting or after re-
ferral by medical personnel. In the 14 intervention HIVST
clusters, resident volunteer counsellors promoted HIVST
and provided pre- and post-test counselling, as well as
directions on how to use the self-test kits. Participants
could self-test in the privacy of their own homes.
Routine and confirmatory HIV testing and care ser-
vices were available at Queen Elizabeth Central Hospital
(QECH), and two primary health clinics located in the
study area (Ndirande Health Centre, Chilomoni Health
Centre). HIVST was provided for a two-year period, with
the service introduced from February to May 2012.
From the onset of intervention in seven HIVST clusters,
and from January 2013 in all HIVST clusters, partici-
pants could also request home-based assessment and
initiation of 14 days of HIV care, including ART if
eligible [14]. Subsequent care was provided at the pri-
mary care level.
The present study recruited participants from February
2013 to April 2014. Recruitment was restricted to adult
residents of the 28 clusters who had just tested for HIV,
either at home (HIVSTclusters) or in a facility (all 28 clus-
ters), but had not started ART. A previously validated
satellite “Map Book” was used to determine cluster of resi-
dence [17], and consequently trial arm. Participants who
accessed HIVST were recruited consecutively from the
Quality Assurance (QA) cohort of the main trial [15]. The
QA component systematically sampled HIVST partici-
pants, with a minimum 5 % randomly selected for home-
visit by one of the trial’s study nurses. Recruitment of
facility-based HTC participants was undertaken consecu-
tively at each of the three local health facilities (Queen
Elizabeth Central Hospital, Ndirande Health Centre and
Chilomoni Health Centre).
Cost analysis
Economic costing of both the HIVST service and facility
HTC services was undertaken to estimate direct health
provider costs [18, 19]. Costs included: staff salaries;
training of staff; consumables and equipment; monitor-
ing and evaluation; and overhead costs, as detailed in
Additional file 1.
HIVST community counsellors, programme managers
and accounting staff were interviewed to estimate the
costs of identified resources and other service delivery,
excluding research costs. For facility HTC services, HTC
counsellors and administrative staff at the Blantyre
District Health Office and the Queen Elizabeth Central
Hospital were interviewed. Trial testing registers and
Ministry of Health programme output data were used to
determine overall numbers of individuals tested and
number of HIV positive individuals identified.
An interviewer-administered questionnaire was devel-
oped that asked all participants recruited into the study
about the direct non-medical and indirect costs that they
or accompanying family member or carers incurred in
accessing HIV testing services. User fees were not charged
for either modality of testing. Direct non-medical costs
included the cost of transportation, food and drinks whilst
waiting, and other costs incurred as a consequence of test-
ing. Indirect costs included time off work multiplied by
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self-reported income [20]. In addition, we recorded the
total time spent testing, including travel and waiting time.
We used data reported by the World Bank to adjust all
costs to account for inflation and differences in purchas-
ing power between countries [21]. All costs are reported
in 2014 US Dollars and International Dollars [19].
Health-related quality of life
Participants were recruited after they had received their
HIV test result, but before starting ART. HIV results and
health-related quality of life (HRQoL) were captured at
the same interview as economic costs. We used a self-
assessed health (SAH) measure to ask individuals to rate
their general health on a five-point Likert scale, with
responses coded as: very good; good; fair; poor; or very
poor. This SAH measure has been found to be a strong
predictor of future health outcomes in high-income set-
tings [22], and has also been used in resource-constrained
settings [23].
A translated Chichewa version of the EuroQoL EQ-5D
[24] tool was used to estimate the HRQoL of all study par-
ticipants. Translation followed EuroQoL guidelines [25],
and was approved before use. The EQ-5D measure con-
sists of two principal measure components, a descriptive
system and a visual analogue scale (VAS) [26]. The de-
scriptive system defines HRQoL on the day of response in
terms of five dimensions: ‘mobility’, ‘self care’, ‘usual activ-
ities’, ‘pain/discomfort’ and ‘anxiety/depression’. Responses
in each dimension have historically been divided into
three ordinal levels, coded: (1) no problems; (2) some or
moderate problems; and (3) severe or extreme problems.
Responses to the three level version of the EQ-5D place
respondents into one of 243 (35) health states. Resultant
health states can be converted to an EQ-5D utility score
using a “tariff set” derived from national surveys of the
general population [26]. As no Malawian EQ-5D tariff
exists, the Zimbabwean EQ-5D tariff set was used [27],
assuming that Malawians will value health comparably
[19]. The Zimbabwean tariff results in EQ-5D utility scores
ranging from 1.0 (no problems in the five dimensions) to
-0.29 (severe problems in all five dimension). The VAS,
similar to a thermometer, ranges from 100 (best imaginable
health state) to 0 (worst imaginable health state). Partici-
pants are asked to indicate how good their health is on the
day of response by drawing a line on the VAS.
Statistical analysis
Analysis used Stata version 13.0 (Stata Corporation, College
Station, TX, USA). Comparisons of categorical variables
used the chi-squared test, with the student’s t-test used for
EQ-5D utility and VAS scores. Principal component ana-
lysis was used to generate wealth quintiles combining
socioeconomic variables including nine household assets,
and home environment variables [28].
Direct health provider cost per individual tested, and
the cost per HIV positive individual identified were esti-
mated from total annual provider cost of HTC services
divided by number of individuals tested and number
testing positive, respectively. For the HIVST, the propor-
tion testing HIV positive was based on overall parent
study data [15]. Direct health provider cost per individ-
ual assessed for ART eligibility, and per ART initiation,
was estimated directly for the facility HTC cohort. The
HIVST cohort data did not capture participants who
were assessed for/initiated on ART by the trial home ini-
tiation option: home initiation events were, therefore,
estimated from the parent trial data. National ART eligi-
bility criteria were used (CD4 count < 350 cells/μl or
WHO stage 3 or 4 or breastfeeding or pregnant).
We made comparisons between the mean direct non-
medical and indirect costs for HIV self-testers and facil-
ity testers, and for facility-testers who resided in control
clusters and intervention clusters. As the cost data were
skewed, we used non-parametric bootstrap methods,
with 1000 bootstrap replications, to derive 95 % confi-
dence intervals (CI) for mean cost differences for rele-
vant cost categories [29].
We undertook multivariate analysis to investigate the
independent effect of the mode of HIV testing and HIV
test result on the total societal costs associated with HIV
testing. Total societal cost summed direct health pro-
vider costs, direct non-medical costs and indirect costs.
For the HIV self-testers, we estimated the direct health
provider cost per individual tested at the counsellor
level. This was possible because the HIVST service re-
cords the total number of individuals tested by each of
the community counsellors. For facility-based HIV tes-
ters, we used the estimated direct health provider cost
per individual tested for the clinic attended for testing.
As all participants incurred a cost, and the cost data
were skewed, we used generalized linear models (GLM)
for multivariate analyses of cost data [30]. We ran model
diagnostics to determine the optimal choices for the
distributional family and link function for these GLM
models [31].
We compared the responses to the SAH and EQ-5D
measures between HIVST participants and all facility
testers, and between facility-based HIV testers residing
in the intervention clusters to those residing in control
clusters. For the descriptive component of the EQ-5D,
binary responses (no problems or some/severe prob-
lems) were used since severe or extreme problems were
rarely reported. We undertook multivariate analysis to
investigate the independent effect of the mode of HIV
testing and HIV test result on the EQ-5D utility score.
EQ-5D utility scores were non-normally distributed,
negatively skewed and truncated at 1.0. We evaluated
four commonly used estimators to analyse these data:
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ordinary least squares (OLS) regression, Tobit regression,
fractional logit regression and censored least absolute de-
viations (CLAD) regression [32–34]. We compared the
mean squared error (MSE) and mean absolute error
(MAE) statistics between the observed EQ-5D utility score
and the estimated scores for the whole sample and for
sub-groups of the sample based on observed EQ-5D utility
scores to determine the choice of estimator.
For all multivariate analyses we ran two alternative
models: the first adjusted for modality of HIV testing,
HIV test result, age and sex, and the second additionally
adjusted for marital status, educational attainment, in-
come and socio-economic position [35]. We accounted
for clustering in all multivariate models using the cluster
of residence for the participants to produce robust vari-
ance estimators.
Sensitivity analysis was carried out using the UK York
A1 tariff for the EQ-5D [36], which translates health
states with ‘severe’ problems in one or more of the five
dimensions into lower EQ-5D utility scores than the
Zimbabwean tariff [27]. For the multivariate analysis of
total societal costs, we performed additional sensitivity
analyses that (i) used the median wage of the sample,
and (ii) the total HIV testing time, to value income
losses (Additional file 1).
Ethical considerations
Ethical approval was obtained from the College of Medi-
cine Ethics Review Committee, University of Malawi, and
the University of Warwick Biomedical Research Ethics
Committee. All participants provided written (or witnessed
thumbprint if illiterate) informed consent.
Results
The study recruited 1,241 participants who had either
self-tested and were being assessed as part of the QA
study (n = 775) or who undertook facility-based HTC
(n = 466) during the study period (Fig. 1). Table 1
shows the characteristics of the participants, by resi-
dence status within the main trial and modality of HIV
testing received. There were no significant differences
in sex, age, marital status, educational attainment, em-
ployment or socioeconomic status between residents of
intervention clusters or control clusters who accessed
facility-based HTC. Figure 2 shows the estimates of
linkage for those who tested HIV positive after facility-
based HTC and HIVST. For facility-based HTC, 75.0 %
to 82.7 % of those identified as HIV positive attended
the HIV clinic for assessment for ART eligibility. For
HIVST, 30.7 % of those identified as HIV positive
attended the HIV clinic for assessment for ART eligibil-
ity, in addition to the estimated 28.3 % opting for home
assessment of HIV care.
The direct health provider costs of facility-HTC and
HIVST are shown in Table 2. The mean provider
costs per individual tested at the three health facilities
were US$7.53 (INT$20.25), US$10.57 (INT$25.18),
and US$8.90 (INT$20.44) at Ndirande, Chilomoni and
QECH, respectively, whilst the mean cost of providing
HIVST was US$8.78 (INT$17.25). The mean provider
costs per HIV positive individual identified were, however,
lower at the three health facilities (range US$28.30-
US$76.14) than for HIVST (US$97.50), reflecting the
lower HIV prevalence among HIVST participants (9.0 %)
than facility HTC participants (range 11.2 %-31.5 %). Simi-
larly, the mean provider costs per HIV positive individual
assessed for ART eligibility (facility range US$37.73 to
US$92.38) and initiated on ART (facility range US$85.75
to US$132.42) were also lower at the three health facilities
than for HIVST (range US$165.14-US$233.90 for eligibil-
ity assessment and US$319.67 for ART initiation).
At the three health facilities, staff salaries accounted for
between 11.1 % and 17.9 % of the total International Dollar
provider costs; the values for staff training varied between
0.5 % and 1.1 %, monitoring and evaluation between 4.2 %
and 11.9 %, and consumables and equipment between
65.5 % and 70.5 %. In comparison, for the HIVST service
staff salaries accounted for 30.3 %, staff training for 13.0 %,
monitoring and evaluation for 20.8 %, and consumables
and equipment for 35.9 % of the total International Dollar
provider cost.
Table 3 shows the time inputs, and direct non-medical
and indirect costs, associated with accessing either
modality of HTC. Most individuals who self-tested did
not incur any costs, need a family member or carer to
accompany them, or take time off work. Approximately
26.6 % (124/466) of all facility testers reported taking
time off work to get tested, and 27 % (126/466) needed a
Fig. 1 Recruitment of HIV testers by study clusters and location of HIV
testing. QECH Queen Elizabeth Central Hospital
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family member or carer to accompany them to the testing
facility. In comparison to HIVST, facility-HTC partici-
pants incurred a mean additional direct non-medical cost
of US$0.84 (bootstrap 95 % CI: US$0.73-US$0.95), whilst
indirect costs were elevated by an average of $1.41 (boot-
strap 95 % CI: US$0.84-US$1.98) with the testing process
taking an additional 177.5 minutes (95 % CI: 165.8-187.2).
The mean combined direct non-medical and indirect cost
of facility-HTC was US$2.93 (bootstrap 95 % CI: US$1.90-
US$3.96) higher than for HIVST.
The mean societal cost per participant tested for facility-
HTC was US$11.84 (95 % CI: US$10.81-12.86) compared
to US$9.23 (95 % CI: US$9.14-US$9.32) for HIVST. In the
multivariate analysis (Table 4), after adjusting for individ-
ual characteristics and HIV test result, the mean societal
cost of HTC was US$2.38 (95 % CI: US$0.87-US$3.89)
lower for HIVST than for facility-HTC.
The HIV test result and HRQoL outcomes are sum-
marized in Table 5. There was no significant difference
between facility testers who resided in the intervention
Table 1 Characteristics of HIV testers
Intervention clusters Control clusters p-valuea
HIVST Facility HTC Facility HTC
All 775 253 213
Sex Male 288 (37 . 2 %) 90 (35 . 6 %) 76 (35 . 7 %) 0 . 981
Age (years) 18-24 316 (40 . 8 %) 64 (25 . 3 %) 64 (30 . 0 %) 0 . 335
25-39 379 (48 . 9 %) 149 (58 . 9 %) 111 (52 . 1 %)
40+ 80 (10 . 3 %) 40 (15 . 8 %) 28 (17 . 8 %)
Marital status Single (never-married) 227 (29 . 3 %) 40 (15 . 8 %) 26 (12 . 2 %) 0 . 606
Married/Cohabiting 455 (58 . 7 %) 175 (69 . 2 %) 148 (69 . 5 %)
Separated/Divorced 78 (10 . 1 %) 24 (9 . 5 %) 24 (11 . 3 %)
Widower/Widow 15 (1 . 9 %) 14 (5 . 5 %) 15 (7 . 0 %)
Educational attainmentb Up to standard 8 300 (38 . 7 %) 132 (52 . 2 %) 124 (58 . 2 %) 0 . 402
Up to form 6 442 (57 . 0 %) 113 (44 . 7 %) 82 (38 . 5 %)
University or training college 32 (4 . 1 %) 8 (3 . 2 %) 7 (3 . 3 %)
Incomec Not working 400 (51 . 6 %) 93 (36 . 8 %) 86 (40 . 4 %) 0 . 752
Up to 4,000 Kwacha/week 162 (20 . 9 %) 79 (31 . 2 %) 56 (36 . 3 %)
4,000 to 8,000 kwacha/week 108 (13 . 9 %) 42 (16 . 6 %) 34 (16 . 0 %)
8,000 to 12,000 kwacha/week 48 (6 . 2 %) 18 (7 . 1 %) 15 (7 . 0 %)
Over 12,000 kwacha/week 57 (7 . 4 %) 21 (8 . 3 %) 22 (10 . 3 %)
Employment status Formal employment 139 (17 . 9 %) 75 (29 . 6 %) 62 (29 . 1 %) 0 . 801
Informal employment/Unemployed 234 (30 . 2 %) 85 (33 . 6 %) 67 (31 . 5 %)
School/University 159 (20 . 5 %) 18 (7 . 1 %) 15 (7 . 0 %)
Retired 2 (0 . 4 %) 1 (0 . 4 %) 1 (0 . 5 %)
Housework 238 (30 . 7 %) 72 (28 . 5 %) 68 (31 . 9 %)
Sick leave 2 (0 . 3 %) 2 (0 . 8 %) 0 (0 %)
Socio-economic positiond Highest quintile 172 (22 . 2 %) 32 (12 . 6 %) 43 (20 . 2 %) 0 . 239
2nd highest quintile 154 (19 . 9 %) 55 (21 . 7 %) 39 (18 . 3 %)
Middle quintile 148 (19 . 1 %) 58 (22 . 9 %) 42 (19 . 7 %)
2nd lowest quintile 145 (18 . 7 %) 55 (21 . 7 %) 48 (22 . 5 %)
Lowest quintile 154 (19 . 9 %) 53 (20 . 9 %) 41 (19 . 2 %)
Had HIV testing in last year Not tested 127 (16 . 4 %) 96 (38 . 0 %) 97 (45 . 5 %) 0 . 048
Tested once 260 (33 . 5 %) 69 (27 . 3 %) 64 (30 . 0 %)
Tested >1 388 (50 . 1 %) 88 (34 . 8 %) 52 (24 . 4 %)
aComparison between facility testers in control and Intervention clusters
bUp to Standard 8 equivalent to completing Primary school; Up to form 6 equivalent to completing Secondary/High school
c426 Malawian Kwacha = US$1 in 2014
dSocio-economic position estimated though undertaking principal component analysis of responses to asset ownership and housing environment
Missing data for Educational attainment: 1; missing data for socio-economic position: 2
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and control clusters with regards to the mean EQ-5D
utility score, the mean VAS score, the descriptive com-
ponents of the EQ-5D measure or their responses to the
SAH measure. A significantly smaller proportion of
HIVST participants who tested HIV negative reported
problems in four of the five EQ-5D dimensions than
compared to facility testers who tested HIV negative
(p < 0.001 for all dimensions excluding “usual activities”).
The mean EQ-5D utility score was higher amongst
HIVST participants (0.905, 95 % CI: 0.897-0.913) than
among facility testers residing in the intervention (0.828,
95 % CI: 0.812-0.844) or control (0.839, 95 % CI: 0.821-
0.857) clusters. The mean VAS score for HIVST partici-
pants was also higher (82.1, 95 % CI: 81.0-83.3) than for
facility-HTC participants residing in the intervention
(74.5, 95 % CI: 72.2-76.8) or control (75.4, 95 % CI: 72.9-
78.0) clusters.
In the multivariate analysis, the model diagnostics
showed that the OLS estimator performed as well or
better than the other estimators (Table 6). In the fully
adjusted OLS model, the mean EQ-5D utility score was
0.046 (95 % CI: 0.022-0.070) higher in individuals who
accessed HIVST than those who accessed facility-HTC.
In those who tested HIV positive the adjusted mean EQ-
5D utility score was 0.048 (95 % CI: 0.024-0.072) lower
than in those who tested HIV negative. There were no
significant differences in the adjusted mean EQ-5D util-
ity scores between facility testers who resided in the
control or intervention clusters.
In the sensitivity analyses, when the UK tariff was used
to derive EQ-5D utility scores, the adjusted mean EQ-
5D utility score was 0.059 (95 % CI: 0.026-0.093) higher
amongst HIVST participants than among facility testers
(Table 6). In addition, those reporting a positive HIV test
result had an even lower mean adjusted utility score
compared to those who reported a negative HIV test
result (mean decrement 0.068; 95 % CI: 0.031-0.105).
Additional file 1 shows that the total societal cost of
HIVST remained lower than for facility-HTC when alter-
native approaches to valuing loss of income were utilised.
Discussion
In this study we found that, compared to facility-based
HIV testing, HIVST reached a population who reported
better health-related quality of life, with users incurring
lower direct non-medical costs and work absences,
whilst the direct health provider costs of offering HIVST
were comparable to facility-based HTC. Consequently,
from the societal perspective, the cost of providing
HIVST was found to be significantly lower than facility-
based HTC services. However, HIVST was costlier than
facility-based HTC for identifying HIV positive individ-
uals for treatment, as is typical for community-based
services where HIV prevalence tends to be lower than in
facilities [11, 12].
In the parent trial, uptake of HIVST was >70 % of all
adult residents each year for two years [15], significantly
greater than current use of facility-based HTC services
in Africa [4]. However, the HIV prevalence amongst
those accessing HIVST was lower, and fewer of those di-
agnosed HIV positive through HIVST linked into HIV
treatment services than through facility-based HTC.
Despite these limitations, well targeted community-
based HTC services are considered essential to reaching
UNAIDS 90-90-90 targets, due to low uptake of facility-
based testing by men, adolescents, remote communities
and key populations [4, 12]. In this context, our data
support HIVST as a potentially affordable approach to
Fig. 2 Linkage into HIV treatment after HIV testing in those eligible for assessment. ART Anti-retroviral therapy, QECH Queen Elizabeth Central Hospital.
*Completed CD4 measurement or WHO stage 3 or 4, **Data from main trial. For logistical reasons, individuals assessed and initiated on ART through
the home-based option were not captured in this cohort
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Table 2 Annual direct health provider costs of HIV testing and counselling
Ndirande clinic Chilomoni clinic QECH HTC clinica HIVST service
Cost category US Dollars
(2014)
INT Dollars
(2014)
% of
Totalb
US Dollars
(2014)
INT Dollars
(2014)
% of
Totalb
US Dollars
(2014)
INT Dollars
(2014)
% of
Totalb
US Dollars
(2014)
INT Dollars
(2014)
% of
Totalb
Staff salaries 6,738 24,545 17 . 9 % 6,433 15,019 11 . 1 % 8,710 24,195 12 . 5 % 23,066 79,431 30 . 3 %
Staff training 353 982 0 . 7 % 530 1,472 1 . 1 % 353 982 0 . 5 % 12,268 34,077 13 . 0 %
Monitoring and evaluation 2,098 5,828 4 . 3 % 5,785 16,069 11 . 9 % 2,920 8,111 4 . 2 % 15,833 54,521 20 . 8 %
Consumables and equipment 38,453 96,475 70 . 5 % 40,910 94,070 69 . 6 % 60,324 126,995 65 . 5 % 82,133 94,051 35 . 9 %
Capital/Overheads 3,257 9,047 6 . 6 % 3,102 8,618 6 . 4 % 12,129 33,691 17 . 4 % 0 0 0
Total annual health
provider cost
50,899 136,876 56,760 135,248 84,436 193,973 133,300 262,080
Individuals tested 6759 5372 9488 15190
Direct cost per individual tested 7 . 53 20 . 25 10 . 57 25 . 18 8 . 90 20 . 44 8 . 78 17 . 25
HIV positive identified 756 743 2984 1367c
Direct cost per HIV
positive identified
67 . 33 181 . 05 76 . 39 182 . 03 28 . 30 65 . 00 97 . 50 191 . 70
Direct cost per HIV positive
individuals assessed for
ART eligibility
83 . 48 224 . 51 92 . 38 220 . 13 37 . 73 86 . 67 165.14 324.67
(173.05)d (340.23)d
(233.90)e (459.86)e
Direct cost per HIV positive initiated
onto ART
109 . 85 295 . 40 132 . 42 315 . 52 85 . 75 196 . 98 319.67 628.50
aOutpatient HIV Testing and counselling clinic at Queen Elizabeth Central Hospital
bPercentages based on costs estimated in International Dollars
cEstimated from HIV prevalence reported in main trial
dHigh linkage rate (56.3 %) from main trial used to estimate cost per individual assessed for ART eligibility [15]
eLow linkage rate (41.7 %) from main trial used to estimate cost per individual assessed for ART eligibility [15]
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providing community services, with high uptake [15]
and provider costs (US$8.78 per HIVST episode in 2014
prices) similar to or lower than mobile or home-based
HTC (US$7.77 to US$33.54 in 2012 prices) [11]. The
higher health provider cost per HIV positive individual
initiated onto ART through HIVST highlights the need
to consider complementary low-cost interventions that
increase linkage into HIV services after HIVST.
The relatively high current cost of the oral fluid RDT
kits (USD$4, or US$4.80 including shipping and insur-
ance), compared to US$0.69 for standard finger-prick
RDT kits used in health facilities, explains much of the
Table 3 Direct non-medical and indirect costs and time inputs
Intervention clusters Control
clusters
Mean differences (95 % CI)c
HIVST (n = 775) Facility HTC (n = 253) Facility HTC
(n = 213)
HIVST V
All Facility HTC
Intervention Facility HTC v
Control Facility HTC
Patient direct non-medical costs
2014 US Dollars (mean/SE) 0 (0, 0)a 0 . 90 (0 . 09) 0 . 78 (0 . 06) -0 . 84 (-0 . 95, -0 . 73) 0 . 12 (-0 . 10, 0 . 33)
2014 INT Dollars (mean/SE) 0 (0, 0)a 2 . 49 (0 . 25) 2 . 17 (0 . 16) -2 . 32 (-2 . 63, -2 . 01) 0 . 32 (-0 . 28, 0 . 92)
Time to get tested (mean/SE)b 30 . 2 (1 . 8) 215 . 2 (7 . 0) 196 . 5 (6 . 9) -176 . 5 (-186 . 9,
-166 . 1)
18 . 7 (-0 . 9, 38 . 3)
Patient time off work Yes 13 (1 . 7 %) 63 (24 . 9 %) 61 (28 . 6 %) - -
Indirect costs
2014 US Dollars (mean/SE) 0 (0, 0)a 1 . 07 (0 . 24) 1 . 93 (0 . 56) -1 . 41 (-1 . 96, -0 . 86) -0 . 87 (-2 . 11, 0 . 38)
2014 INT Dollars (mean/SE) 0 (0, 0)a 2 . 97 (0 . 67) 5 . 37 (1 . 55) -3 . 91 (-5 . 44, -2 . 38) -2 . 41 (-5 . 87, 1 . 05)
Family or carer accompanied Yes 13 (1 . 7 %) 65 (25 . 7 %) 61 (28 . 6 %) - -
Family/carer direct non-medical costs
2014 US Dollars (mean/SE) 0 (0, 0)a 0 . 24 (0 . 04) 0 . 26 (0 . 04) -0 . 25 (-0 . 31, -0 . 19) -0 . 02 (-0 . 13, 0 . 10)
2014 INT Dollars (mean/SE) 0 (0, 0)a 0 . 68 (0 . 11) 0 . 72 (0 . 11) -0 . 70 (-0 . 86, -0 . 54) -0 . 04 (-0 . 36, 0 . 27)
Family/carer time to accompany to test
(mean/SE)b
0 (0, 0)a 54 . 3 (6 . 8) 51 . 8 (6 . 4) -52 . 4 (-43 . 3, -61 . 5) 2 . 5 (-16 . 5, 21 . 5)
Family/carer loss of income
2014 US Dollars (mean/SE) 0 (0, 0)a 0 . 03 (0 . 02) 1 . 29 (0 . 95) -0 . 59 (-1 . 43, 0 . 25) -1 . 25 (-3 . 16, 0 . 65)
2014 INT Dollars (mean/SE) 0 (0, 0)a 0 . 09 (0 . 05) 3 . 57 (2 . 65) -1 . 64 (-3 . 97, 0 . 69) -3 . 48 (-8 . 70, 1 . 72)
Total direct non-medical and indirect costs
2014 US Dollars (mean/SE) 0 (0, 0)a 2 . 22 (0 . 27) 3 . 91 (1 . 09) -2 . 93 (-3 . 94, -1 . 92) -1 . 69 (-3 . 88, 0 . 51)
2014 INT Dollars (mean/SE) 0 (0, 0)a 6 . 18 (0 . 74) 10 . 87 (3 . 02) -8 . 14 (-10 . 94, -5 . 35) -4 . 69 (-10 . 73, 1 . 36)
SE standard error
aMedian and IQR reported because of low numbers incurring costs/taking time off work
bTime measured in minutes and includes travel to and from testing site, waiting time and counselling and testing time
cBootstrapped estimates of mean differences and 95 % CI
Table 4 Multivariate Analysis exploring relationship between modality of HIV testing and total societal cost of testinga
Total societal cost
Model 1 (n = 1240) Model 2 (n = 1237)
2014 US Dollars 2014 INT Dollars 2014 US Dollars 2014 INT Dollars
Coef (95 % CI) Coef (95 % CI) Coef (95 % CI) Coef (95 % CI)
Exposure Control clusters: Facility HTC Ref Ref Ref Ref
Intervention clusters: Facility HTC -1 · 45 (-3 · 62, 0 · 73) -4 · 24 (-9 · 99, 1 · 52) -0 · 98 (-2 · 59, 0 · 63) -2 · 97 (-7 · 07, 1 · 13)
Intervention clusters: HIVST -3 · 01 (-5 · 14, -0 · 88) -12 · 52 (-18 · 23, -6 · 82) -2 · 38 (-3 · 89, -0 · 87) -10 · 82 (-14 · 79, -6 · 87)
HIV Test Result HIV negative Ref Ref Ref Ref
HIV positive 1 · 19 (-0 · 04, 2 · 41) 2 · 76 (-0 · 29, 5 · 81) 1 · 11 (0 · 24, 1 · 99) 2 · 57 (0 · 41, 4 · 72)
Model 1: adjusted for exposure, HIV test result, age and sex
Model 2: additionally adjusted for marital status, educational attainment, income and wealth quintile
Missing data for HIV test result: 1; missing data for educational attainment: 1; missing data for socio-economic position: 2
aFindings from Generalized Linear Model with Poisson distribution and Identity link function
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Table 5 Health-related quality of life of HIV testers
Intervention clusters Control clusters HIVST v Intervention
Facility
HTC v Control
Facility HTC
All Facility
HTC
HIVST (n = 775) Facility HTC
(n = 253)
Facility HTC
(n = 213)
p-value p-value
HIV test result (n/%) HIV negative 670 (86 . 5 %) 146 (57 . 7 %) 115 (54 . 0 %) 0 . 421
HIV positive 104 (13 . 4 %) 107 (42 . 3 %) 98 (46 . 0 %) <0 . 001
Not reported 1 (0 . 1 %) 0 (0 %) 0 (0 %)
EQ-5D: Utility
score (mean/SE)
All 0 . 905 (0 . 897, 0 . 913) 0 . 828 (0 . 812, 0 . 844) 0 . 839 (0 . 821, 0 . 857) <0 . 001 0 . 359
HIV negative 0 . 916 (0 . 908, 0 . 924) 0 . 853 (0 . 834, 0 . 873) 0 . 862 (0 . 839, 0 . 884) <0 . 001 0 . 591
HIV positive 0 . 842 (0 . 814, 0 . 870) 0 . 794 (0 . 768, 0 . 819) 0 . 813 (0 . 786, 0 . 840) 0 . 022 0 . 306
EQ-5D: VAS score
(mean/SE)
All 82 . 1 (81 . 0, 83 . 3) 74 . 5 (72 . 2, 76 . 8) 75 . 4 (72 . 9, 78 . 0) <0 . 001 0 . 597
HIV negative 83 . 7 (82 . 5, 84 . 9) 79 . 4 (76 . 6, 82 . 2) 79 . 5 (76 . 0, 82 . 9) <0 . 001 0 . 966
HIV positive 72 . 5 (69 . 0, 76 . 0) 67 . 9 (64 . 4, 71 . 3) 70 . 7 (67 . 0, 74 . 4) 0 . 135 0 . 270
EQ-5D: Mobility (n/%) Moderate or
severe
problems
HIV negative 61 (9 . 1 %) 34 (23 . 3 %) 17 (14 . 8 %) <0 . 001 0 . 085
HIV positive 23 (22 . 3 %) 40 (37 . 0 %) 33 (34 . 0 %) 0 . 018 0 . 652
EQ-5D: Self-care (n/%) Moderate
or severe
problems
HIV negative 5 (0 . 7 %) 2 (1 . 4 %) 1 (0 . 9 %) 0 . 551 0 . 707
HIV positive 3 (2 . 9 %) 6 (5 . 6 %) 1 (1 . 0 %) 0 . 815 0 . 075
EQ-5D: Usual activities
(n/%)
Moderate
or severe
problems
HIV negative 25 (3 . 7 %) 19 (13 . 0 %) 13 (11 . 3 %) <0 . 001 0 . 676
HIV positive 19 (18 . 4 %) 26 (24 . 1 %) 25 (25 . 8 %) 0 . 204 0 . 779
EQ-5D: Pain (n/%) Moderate
or severe
problems
HIV negative 159 (23 . 8 %) 55 (37 . 7 %) 50 (43 . 5 %) <0 . 001 0 . 342
HIV positive 50 (48 . 5 %) 68 (63 . 0 %) 50 (51 . 5 %) 0 . 134 0 . 099
EQ-5D: Anxiety (n/%) Moderate
or severe
problems
HIV negative 212 (31 . 7 %) 71 (48 . 6 %) 49 (42 . 6 %) <0 . 001 0 . 333
HIV positive 44 (42 . 7 %) 57 (52 . 8 %) 53 (54 . 6 %) 0 . 070 0 . 790
Self-assessed health
(n/%)
Poor or
very poor
HIV negative 6 (0 . 9 %) 6 (4 . 1 %) 5 (4 . 3 %) 0 . 001 0 . 924
Poor or
very poor
HIV positive 5 (4 . 9 %) 13 (12 . 0 %) 9 (9 . 3 %) 0 . 085 0 . 524
Table 6 Multivariate analysis exploring relationship between modality of HIV testing and EQ-5D utility scoresa
EQ-5D Utility Score (Zimbabwean Tariff) EQ-5D Utility Score (UK Tariff)b
Model 1 (n = 1240) Model 2 (n = 1237) Model 1 (n = 1240) Model 2 (n = 1237)
Coef (95 % CI) Coef (95 % CI) Coef (95 % CI) Coef (95 % CI)
Mode of HIV
testing
Control clusters: Facility
HTC
Ref Ref Ref Ref
Intervention clusters: Facility
HTC
-0 · 012 (-0 · 038, 0 · 014) -0 · 011 (-0 · 037, 0 · 015) -0 · 145 (-0 · 055, 0 · 026) -0 · 012 (-0 · 053, 0 · 029)
Intervention clusters: HIVST 0 · 043 (0 · 018, 0 · 068) 0 · 046 (0 · 022, 0 · 070) 0 · 059 (0 · 026, 0 · 092) 0 · 065 (0 · 031, 0 · 099)
HIV test result HIV negative Ref Ref Ref Ref
HIV positive -0 · 054 (-0 · 077, -0 · 031) -0 · 048 (-0 · 073, -0 · 024) -0 · 076 (-0 · 112, -0 · 040) -0 · 068 (-0 · 105, -0 · 031)
Model 1: adjusted for exposure, HIV test result, age and sex
Model 2: additionally adjusted for marital status, educational attainment, income and wealth quintile
Missing data for HIV test result: 1; missing data for educational attainment: 1; missing data for socio-economic position: 2
aFindings from OLS estimator
bFindings from sensitivity analysis
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variation. In our analysis the cost of oral fluid RDT kits
accounted for half of the total cost per individual tested
through HIVST, whilst finger-prick RDT kits accounted
for only one tenth of the cost of facility-based HIV testing.
In 2010 alone, nearly 100 million HIV testing episodes
were undertaken in Africa [37]. Given the steady increase
in uptake of HTC since then [3], and projected needs to
meet global targets [5], manufacturers need to be aware of
the massive potential market for low cost, easily useable
and disposal HIVST kits. In the meantime, scaling-up
HIVST will require donor-provision of self-test kits,
ideally with negotiation of lower prices through bulk pro-
curement for low- and middle-income countries.
We compared both health provider and societal costs
of HIVST and facility-based HTC. Health care costing
studies and economic evaluations predominantly adopt a
health provider perspective as the findings are used to
inform how best to allocate finite health care resources.
Taking into account the costs at the societal level in-
forms us on the wider impact of healthcare interventions
on the economy as a whole, and may explain reasons for
sub-optimal uptake by the population served. Previous re-
search highlights that high direct non-medical and indir-
ect costs act as a deterrent to accessing facility-based
HTC services [6, 38, 39]. In comparison to HIVST, we
found facility testing was associated with a mean add-
itional direct non-medical and indirect cost of US$2.93. In
Malawi approximately three-quarters of the population
live on less than $2 a day [40]. It is clear that the high cli-
ent costs of accessing facility-based HTC are likely to act
as a deterrent, and this may partly explain the high levels
of uptake of HIVST seen in the main trial [15].
HIV testing and counselling has been provided at health
facilities in Africa for over a decade. HIV counsellors at
health facilities are experienced in providing HTC, and
monitoring and evaluation systems have evolved. In con-
trast, HIVST is still in its infancy, with concerns remaining
(albeit not supported by current evidence) around potential
social harms [41]. Consequently, in the main trial, HIVST
was provided through a semi-supervised semi-restricted
community distribution model that incurred considerable
training and supervision costs: salaries, staff training, and
monitoring and evaluation accounted for approximately
two-thirds of the cost of delivering HIVST, in comparison
to less than one quarter for facility-based HTC. Less costly
HIVST distribution models will almost certainly develop as
experience accrues (e.g. counselling provided by telephone
hotlines), even without the anticipated reduction in the
unit cost of kits.
We used the average yield from the HIVST service
over the two years in operation to estimate the health
provider cost per HIV positive individual identified
through HIVST, assuming individuals were offered an-
nual HIVST. In the main trial, there was a ‘prevalence
round’ effect, with HIV prevalence amongst self-testers
found to be higher in the first year than in the second
[15]. It is likely that the costs per HIV positive individual
identified will continue to rise over the years of oper-
ation as the number of undiagnosed HIV infected indi-
viduals in the community falls.
The EQ-5D measure provides two assessments of
HRQoL, the EQ-5D utility score and the VAS score. The
VAS score reflects individuals’ self-assessment of their
health status, whilst the EQ-5D utility score reflects a
general population preference for the overall health state
delineated across five dimensions with the added benefit
that utility scores can inform cost-utility analyses. In our
study we found HIV self-testers reported higher VAS
scores than those who tested in facility services. HIV
self-testers do not have their test result communicated
to them by a HIV counsellor, and the higher VAS scores
suggests this does not negatively impact on an individ-
ual’s HRQoL. Those who self-tested reported higher EQ-
5D utility scores than those who accessed facility testing
services, even after accounting for differences in HIV
test result and socio-demographic characteristics. Previ-
ous work from the main trial found the median CD4
count amongst HIV self-testers who initiated ART to be
higher than facility-based testers who initiated ART [15].
Moving HIV testing into the community potentially
reaches a population whose HIV infection has not ad-
vanced sufficiently to result in their attendance at a
health facility.
Also notable is that, despite the high uptake of HIVST
in the main trial [15], intervention cluster residents con-
tinued to access facility-based HTC services, highlighting
the complementary nature of the two models of provision.
Facility HTC provides services that cannot be replaced in
community, such as diagnostic HIV testing for manage-
ment of illness (e.g. TB patients) and provider initiated
testing for prevention of mother-to-child transmission
[42]. In contrast, community-based services are intended
to provide healthy individuals with the means of knowing
their status on a regular basis, and providing early linkage
into HIV treatment and prevention services [14, 15].
This is the first study we are aware of that has estimated
the costs of providing HIVST in Africa. We explored in
detail all costs associated with HIVST, from the health
provider and societal perspectives, compared with facility-
based HIV testing, as well as the HRQoL of users of both
modalities. We undertook a range of sensitivity analyses
to explore the impact of alternative approaches to estimat-
ing total societal costs and for valuing HRQoL. This is
not, however, a full economic evaluation, and we, there-
fore, cannot comment on whether or not scaling-up
HIVST is a cost-effective option for sub-Saharan Africa. A
full economic evaluation would need to incorporate the
costs of providing subsequent HIV treatment and the
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health outcomes of HIV positive individuals identified
through the two modalities, among other considerations.
Conclusions
HIV testing services in Africa are in urgent need of sub-
stantial scale-up. HIVST offers a potential option, and
offering it reduces the economic burden on clients.
However, enhanced HIVST strategies may be needed to
target higher risk individuals or to increase linkage into
HIV treatment services amongst those found to be HIV
positive. The affordability of HIVST would substantially
improve if the costs of HIV self-test kits were lower, or if
HIVST could be provided safely and effectively through
less restricted and supervised models. Further work is
needed to explore the cost-effectiveness of HIVST.
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